Condition

Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

ClinicalTrials.gov condition label

Clinical trials1

Recruiting0

Common interventions1

Lead sponsors shown1

Clinical trials

1 shown

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsNCT04482309 · 2020-08-18

ACTIVE_NOT_RECRUITING

Common interventions

Trastuzumab deruxtecanDRUG1

Leading sponsors

AstraZeneca1

Trial status mix

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.